计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Danusertib (PHA-739358)是一种Aurora kinase抑制剂,作用于Aurora A/B/C时IC50为13 nM/79 nM/61 nM,适度有效作用于Abl, TrkA, c-RET和FGFR1,对Lck, VEGFR2/3, c-Kit, CDK2等作用效果稍弱。
Danusertib(PHA-739358),是吡咯并吡咯子系列的3-aminopyrazole衍生物,是aurora激酶家族的小分子抑制剂,显著抑制aurora B激酶(ABK)。这种pan-aurora激酶抑制剂还能够抑制其他的酪氨酸激酶,包括T315I突变体、RET、TRK-A和成纤维细胞生长因子受体-1(FGFR-1),这些酪氨酸激酶参与多种恶性肿瘤的形成,例如慢性髓性白血病( CML)、急性淋巴细胞白血病(ALL)、甲状腺前列腺癌和乳腺癌。之前的研究表明,在不同的异种移植、自发的和转基因动物肿瘤模型中,danusertib具有显著的抗肿瘤活性,并具有有利的药代动力学和安全性。
Danusertib (PHA-739358)是一种Aurora kinase抑制剂,作用于Aurora A/B/C,无细胞试验中IC50为13 nM/79 nM/61 nM,适度有效作用于Abl,TrkA,c-RET和FGFR1,对Lck,VEGFR2/3,c-Kit,CDK2等作用效果稍弱。Danusertib 可诱导凋亡、细胞周期阻滞和自噬。
Information
Danusertib (PHA-739358) is anAurora kinaseinhibitor forAurora A/B/CwithIC50of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Danusertib inducesapoptosis, cell cycle
In vitro
Danusertib inhibits the activities of other kinases such as FGFR1, Abl, Ret and Trka, with IC50 of 47 nM, 25 nM, 31 nM and 31 nM, respectively. In a cell assay, after treatment of wild-type and p53-deficient MEFs with Danusertib, the wild-type cells undergo an arrest in mitosis (4N) that is maintained for up to 48 h. The p53-deficient cells on the other hand do not arrest at the 4N DNA stage, but continues with additional rounds of DNA synthesis to become >8N. Treatment with Danusertib results in an increase in p53 protein levels and an associated increase in p21 protein, which is known to be transcriptionally regulated by p53. Increasing concentrations of Danusertib produces a dose-dependent reduction of cell growth after 48 hours in BCR-ABL-positive (K562, BV173) and BCR-ABL-negative (HL60) cells.
In vivo
Administration of 25 mg/kg Danusertib (b.d. i.v.) to HL-60 xenograft rats results in 75% inhibition of tumor growth with complete regression in one animal. Danusertib results in biomarker modulation accompanied by inhibition of tumor growth. This is compatible with an expected mechanism of action of aurora kinase inhibition. Danusertib significantly inhibits proliferation of K562 cells and virtually suppressed tumor growth during the 10-day treatment period.
Cell Data
cell lines:
Concentrations:5 μM
Incubation Time:5 days
Powder Purity:≥95%
| ALogP | 1.8 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | D408823 |